Clinical trials: Advanced Solid Tumor Malignancies
Pan Tumor
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
- Trial name
- CheckMate 848 (NCT03668119)
- Testing
- Nivolumab, Ipilimumab
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Malignant Neoplasm
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise.
- Trial name
- NCT03808870
- Testing
- NBM-BMX softgel capsules
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- NatureWise Biotech & Medicals Corporation
Advanced / Metastatic Solid Tumors
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.
- Trial name
- NCT05425602
- Testing
- MAX-40279-01: 50mg/70mg
- Volunteers
- 108 people
- Sponsor
- Maxinovel Pty., Ltd.
Advanced Solid Tumors
Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer
The goal of this clinical trial is to assess the safety and tolerability of YY2201 in participants with advanced solid tumors. The main questions it aims to answer are: What medical problems do participants have when taking drug…
- Trial name
- NCT06976931
- Testing
- YY2201
- Volunteers
- 42 people
- Sponsor
- Jiangsu YaYao Biotechnology Co., Ltd.
Malignant Neoplasm of Digestive System
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2).
- Trial name
- NCT05639153
- Testing
- DR30303
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Solid Tumors
A Study of ERY974 in Patient With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity.
- Trial name
- NCT02748837
- Testing
- ERY974
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Chugai Pharmaceutical
Solid Tumor
A Study of LY3415244 in Participants With Advanced Solid Tumors
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT03752177
- Testing
- LY3415244
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT04471675
- Testing
- Albumin-bound docetaxel
- Where
- China
- Volunteers
- 208 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Renal Cell Carcinoma, Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended…
- Conditions
- Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
- Trial name
- NCT06010875
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
Study to evaluate the safety and tolerability of intravenous ICVB-1042
- Trial name
- ICVB-1042 (NCT05904236)
- Testing
- Treatment with ICVB-1042 administered intravenously
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- IconOVir Bio
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Solid Tumor
Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
- Trial name
- NCT00920595
- Testing
- CEP-9722
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Cephalon
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Solid Tumor
A Study of AK131 in Patients With Advanced Solid Tumors
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
- Trial name
- NCT06166888
- Testing
- AK131
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Akeso
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumors, Lymphoma, Non-Hodgkin
Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas
This Phase 1 escalating-dose study is designed to assess, the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel proteasome inhibitor CEP 18770, given intravenously as single agent, in patients with…
- Trial name
- NCT00572637
- Testing
- CEP-18770
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 55 people
- Sponsor
- Ethical Oncology Science
CRC
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Trial name
- NCT07511972
- Testing
- NGM707 plus pembrolizumab
- Sponsor
- NGM Biopharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.